The developer of cannabis-based medications is now under new ownership.
News & Analysis: Jazz Pharmaceuticals
JAZZ earnings call for the period ending March 31, 2021.
The company beat top-line estimates, but missed on the bottom line.
JAZZ earnings call for the period ending December 31, 2020.
Jazz is paying $7.2 million to buy the maker of CBD-derived drug Epidiolex. Is it a smart deal?
This troubled biopharma is making a multi-billion dollar bet on the cannabis industry in hopes of a turnaround.
A second term for Trump would be music to the ears of these four companies.
Drug developers don't get much cheaper than this.
In case of a flash sale, scoop up shares of companies that are bound to bounce back.
Despite a poor performance of late, this biotech stock could bounce back.